Covidien Receives FDA Approval for Morphine Sulfate Oral Solution

Covidien COV today announced that the U.S. Food and Drug Administration recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).